文献速递心脑血管急症重症综合管理与镇静镇痛

羟钴胺成功逆转尼莫地平诱导的难治性血管麻痹:蛛网膜下腔出血一例

Rescue of Nimodipine-Induced Refractory Vasoplegia With Hydroxocobalamin in Subarachnoid Hemorrhage: A Case Report.
PubMed 文献 · Crit Care Explor · 2020-09-23
一句话结论蛛网膜下腔出血患者单剂肠内尼莫地平后出现对三种升压药无效的难治性血管麻痹,5 g 静脉羟钴胺(15 分钟输注)后血流动力学即刻改善并快速停用升压药。

本文报告一例 84 岁男性因蛛网膜下腔出血昏迷,在单剂肠内尼莫地平后出现严重低血压,对三种升压药无反应。床旁多系统超声排除其他休克病因,提示尼莫地平所致血管麻痹状态。因考虑一氧化氮代谢受损为血管麻痹驱动因素,给予 5 g 静脉羟钴胺输注 15 分钟,血流动力学即刻改善并快速停用升压药;患者出现色尿但无其他不良反应。作者认为这是首例成功使用羟钴胺作为尼莫地平诱导血管麻痹潜在挽救治疗的报告,并提出考虑作用于一氧化氮介导血管舒张药物及其不良反应谱的血管麻痹治疗算法。

要点

  • 蛛网膜下腔出血患者单剂肠内尼莫地平后出现对三种升压药无反应的严重低血压,床旁多系统超声排除其他休克病因后考虑为尼莫地平所致血管麻痹。
  • 给予 5 g 静脉羟钴胺输注 15 分钟后血流动力学即刻改善,并快速停用升压药。
  • 患者出现色尿,无其他与羟钴胺相关的不良反应。
  • 作者认为这是首例成功使用羟钴胺作为尼莫地平诱导血管麻痹潜在挽救治疗的报告,并提出血管麻痹治疗算法。

适用人群与场景

  • 84 岁男性,因蛛网膜下腔出血昏迷,在单剂肠内尼莫地平后出现严重低血压且对三种升压药无反应。

处置流程与药物剂量

  • 因考虑一氧化氮代谢受损为血管麻痹驱动因素,给予 5 g 静脉羟钴胺输注 15 分钟;输注后血流动力学即刻改善并快速停用升压药。

研究设计与关键结果

  • 病例报告:84 岁男性蛛网膜下腔出血昏迷患者,单剂肠内尼莫地平后出现对三种升压药无反应的严重低血压;床旁多系统超声排除其他休克病因,提示尼莫地平所致血管麻痹。
  • 给予 5 g 静脉羟钴胺输注 15 分钟后血流动力学即刻改善并快速停用升压药;患者出现色尿,无其他不良反应。
  • 作者认为这是首例成功使用羟钴胺作为尼莫地平诱导血管麻痹潜在挽救治疗的报告,并提出血管麻痹治疗算法。

证据类型、等级与局限

  • 证据类型:病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 尼莫地平是蛛网膜下腔出血减少脑血管痉挛不良结局的标准实践,轻度低血压为常见不良反应,罕见情况下可发展为严重低血压导致难治性血管麻痹;原文指出尼莫地平诱导血管麻痹尚无逆转剂证据基础,作者认为本病例首次证明羟钴胺可作为潜在挽救治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We report a case of refractory vasoplegia after nimodipine administration that was unresponsive to triple vasopressor therapy and was rescued by IV hydroxocobalamin.

CASE SUMMARY: An 84-year-old male presented comatose from a subarachnoid hemorrhage and developed severe hypotension unresponsive to three vasopressors following a single dose of enteral nimodipine. Multisystem point-of-care ultrasonography ruled out alternate etiologies of shock, indicating that this was likely a vasoplegic state caused by nimodipine. We administered 5 grams of IV hydroxocobalamin over 15 minutes due to the possibility of impaired nitric oxide metabolism as the driver of vasoplegia. This led to immediate improvement in hemodynamics and rapid discontinuation of vasopressors. The patient experienced chromaturia but no other adverse effects due to hydroxocobalamin.

CONCLUSIONS: Nimodipine administration is a standard practice for patients with aneurysmal subarachnoid hemorrhage to reduce unfavorable outcomes from cerebral vasospasm. Although mild hypotension is a common side effect of nimodipine, in rare cases, it may become profound, leading to refractory vasoplegia. There is no evidence-base for reversal agents for nimodipine-induced vasoplegia, and this case is the first to demonstrate successful use of hydroxocobalamin as a potential rescue therapy. We also propose an algorithm for treatment of vasoplegia with consideration of medications that act on nitric oxide-mediated vasodilation and their side-effect profiles.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Clifford KM, Madhok J, Murray NM, et al. Rescue of Nimodipine-Induced Refractory Vasoplegia With Hydroxocobalamin in Subarachnoid Hemorrhage: A Case Report. Crit Care Explor. 2020. PMID: 33063021. doi:10.1097/CCE.0000000000000205

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。